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ercutaneous Transcatheter Mitral Valve Repair
Classification of the Technology
aul T. L. Chiam, MBBS,* Carlos E. Ruiz, MD, PHD†
ingapore; and New York, New York
urgical treatment of mitral regurgitation (MR) has evolved from mitral valve replacement (MVR) to
epair (MVRe), because MVRe produces superior long-term outcomes. In addition, MVRe can be
chieved through minimally invasive approaches. This desire for less invasive approaches coupled with
he fact that a signiﬁcant proportion of patients—especially elderly persons or those with signiﬁcant
omorbidities or severe left ventricular (LV) dysfunction, are not referred for surgery, has driven the
eld of percutaneous MVRe. Various technologies have emerged and are at different stages of investi-
ation. A classiﬁcation of percutaneous MVRe technologies on the basis of functional anatomy is pro-
osed that groups the devices into those targeting the leaﬂets (percutaneous leaﬂet plication, percuta-
eous leaﬂet coaptation, percutaneous leaﬂet ablation), the annulus (indirect: coronary sinus approach
r an asymmetrical approach; direct: true percutaneous or a hybrid approach), the chordae (percutane-
us chordal implantation), or the LV (percutaneous LV remodeling). The percutaneous edge-to-edge
epair technology has been shown to be noninferior to open repair in a randomized clinical trial (EVER-
ST II [Endovascular Valve Edge-to-Edge REpair Study]). Several other technologies employing the con-
epts of direct and indirect annuloplasty and LV remodeling have achieved ﬁrst-in-man results. Most
ikely a combination of these technologies will be required for satisfactory MVRe. However, MVRe is not
ossible for many patients, and MVR will be required. Surgical MVR is the standard of care in such pa-
ients, although percutaneous options are under development. (J Am Coll Cardiol Intv 2011;4:1–13)
2011 by the American College of Cardiology Foundationg
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Titral regurgitation (MR) is a common valvular
bnormality, being present in 24% of adults with
alvular heart disease and in 7% of the population
75 years of age (1,2). Surgical intervention is
ecommended for symptomatic severe MR or
symptomatic severe MR with left ventricular (LV)
ysfunction or enlargement (3). Treatment of se-
ere degenerative MR has evolved from mitral
alve replacement (MVR) to mitral valve repair
MVRe) (3), because repair produces superior out-
omes (4,5). For functional MR, however, the
enefit of repair over MVR is less certain (6)
rom the *Department of Cardiology, National Heart Centre, Singa-
ore, Singapore; and the †Department of Cardiac and Vascular Inter-
entional Services, Lenox Hill Heart and Vascular Institute of New
ork, New York, New York. Dr. Chiam reports that he has no
elationships to disclose. Dr. Ruiz is a consultant for CoreValve.a
anuscript received June 14, 2010; revised manuscript received Septem-
er 8, 2010, accepted September 17, 2010.With increased understanding of the hetero-
enic pathophysiology of MR, cardiac surgeons
ave developed various techniques that increase the
ikelihood of successful repair (7). Mitral valve
epair can also be achieved through minimally
nvasive approaches (8,9). This desire for less
nvasive approaches coupled with the fact that a
ignificant proportion of patients—especially el-
erly persons or those with significant comorbidi-
ies or severe LV dysfunction—are not referred for
urgery (10) has driven the field of percutaneous
VRe. Various technologies have emerged and are
t different stages of investigation.
ercutaneous Approaches to
itral Valve (MV) Therapies
he MV is just one of the elements of the mitral
pparatus, and as such pathologies affecting the
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2nnulus (mitral annulus [MA]), leaflets, papillary muscle,
hordae tendineae, LV, and left atrium (LA) can all produce
r contribute to MR. The functional anatomy and classifi-
ation of MR have been reviewed recently (7) and would not
e further discussed. Surgical techniques are primarily
imed at correcting the culprit mechanism(s) (e.g., pro-
apsed leaflet, annular dilation) that lead to MR (7), and a
ombination of techniques may be used to obtain the best
utcome. These surgical techniques can be broadly classified
nto those aimed at the leaflets, MA, commissures, chordae,
apillary muscles, and LV. Current percutaneous technol-
gies for MVRe have been developed on the basis of some
f these surgical principles.
These technologies have been previously grouped into
hose acting on the leaflets, direct annuloplasty or indirect
nnuloplasty (via the coronary sinus [CS]), and chamber
LV) remodeling (11–15). A modified classification of
ercutaneous MVRe technology according to functional
natomy and device action is proposed (Table 1). This
might facilitate more precise de-
scription of the current devices
and accommodate emerging
technologies.
Percutaneous Leaflet
Plication (Edge-to-Edge
Leaflet Repair)
Principle. The leaflet plication
technology is based on the sur-
gical Alfieri technique (16),
which brings the anterior and
posterior leaflets together with a
suture, creating a “double ori-
fice” MV. This re-establishes
eaflet coaptation, thereby reducing MR. This technique is
ost suitable for degenerative MR, although it could be
mployed in functional MR.
evices. The MitraClip (Abbott Vascular, Santa Clara, Cal-
fornia) system uses a steerable catheter to deliver a clip to the
nterior leaflet and posterior leaflet via transseptal access
Fig. 1). The safety and feasibility study (EVEREST I [En-
ovascular Valve Edge-to-Edge REpair Study]) (17) showed
hat, in 107 patients, procedural success (post-procedure MR
2) was achieved in 74% with 1% in-hospital mortality
17). At 1-year, freedom from death, MV surgery or MR2
as 66%. Freedom from death and freedom from surgery were
0.1% and 76.3% at 3 years, respectively. No clip embolized,
lthough partial clip detachment occurred in 10 patients (9%).
ubsequently, 32 patients required surgery for MR; repair—
hen planned—was possible in 84%, demonstrating that
urgical options were preserved (17,18).
Data from the EVEREST II study, randomizing Mitra-
bbreviations
nd Acronyms
S  coronary sinus
IM  first-in-man
A  left atrium
V  left ventricle
A  mitral annulus
R  mitral regurgitation
S  mitral stenosis
V  mitral valve
VR  mitral valve
eplacement
VRe  mitral valve repairlip versus surgical repair, were recently presented (Amer- dcan College of Cardiology 2010). Patients (n  279) with
ymptomatic severe MR or asymptomatic severe MR with
V dysfunction were randomized in a 2:1 (device: surgery)
ashion. Freedom from combined end point of death, MV
urgery or reoperation 90 days after index procedure, and
R 2 at 1 year was 72.4% and 87.8% in the device and
urgical groups, respectively, meeting the noninferiority
ypothesis. The safety end point (all predefined adverse
vents plus blood transfusions 2 U) was superior in the
evice group (9.6% vs. 57% for surgery). The MitraClip
hus seems to be an alternative option for selected patients.
The Mobius device (Edwards Life Sciences, Irving,
alifornia) used a suture to create a double orifice MV.
espite feasibility in the animal model, initial human
xperience was limited by suture dehiscence and technical
ifficulties (19), and the program has been abandoned.
The MitraFlex (TransCardiac Therapeutics, Atlanta,
eorgia), which deploys a clip to the leaflets via the
ransapical route, is undergoing pre-clinical testing (this
evice also allows an artificial chord to be implanted during
he same procedure).
imitations. The major limitation of this percutaneous
echnology is that the surgical Alfieri technique is typically
sed with an annuloplasty, because results without annulo-
lasty have been suboptimal with significant rates of recur-
ent MR and need for reoperation (20), especially in
schemic MR (21) or if annular calcification is present (20).
owever, in a small group of well-selected patients, 90%
reedom from recurrent MR 2 or reoperation at 5 years
ould be achieved (22). Another limitation is the possibility
f causing iatrogenic mitral stenosis (MS) (7), although
errmann et al. (23) reported no significant stenosis in 96
atients with successful MitraClip(s) implanted.
eaflet Ablation
rinciple. Radiofrequency energy is delivered to the leaf-
et(s) to effect structural (fibrosis) or functional (reduced
otion) alteration. This technology is designed to target
egenerative MR.
evice. The Thermocool irrigation ablation electrode (Bio-
ense Webster, Inc., Diamond Bar, California) is a radiofre-
uency ablation (RFA) catheter that is delivered via femoral
rtery access retrograde into the LV. The catheter is placed in
ontact with the anterior leaflet, and RFA is delivered, causing
carring and fibrosis and reduced leaflet motion. Proof-of-
oncept was demonstrated in an animal study (24).
imitations. Scarring and fibrosis from the RFA might not be
recise, resulting in too-long or too-short post-ablation leaflet
ith residual or even worsening MR. Leaflet perforation and
amage to adjacent cardiac structures might occur.
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3eaflet Space Occupier
rinciple. A device acting like a “buoy” is positioned across
he MV orifice to provide a surface against which the leaflets
an coapt, reducing MR. This could be applied to degen-
rative or functional MR.
evice. The Percu-Pro device (Cardiosolutions, Stough-
Table 1. Percutaneous MVRe and MVR Technologies
Site of Action Mechanism of Action Device
Percutaneous
Leaﬂets Edge-to-edge (leaﬂet plication) MitraClip
MitraFlex
Space occupier (leaﬂet
coaptation)
Percu-Pro
Leaﬂet ablation Thermocool
Annulus Indirect annuloplasty
● Coronary sinus approach
(CS reshaping)
Monarc
Carillon
Viacor
● Asymmetrical approach St. Jude device
NIH-Cerclage technology
Direct annuloplasty
● Percutaneous mechanical
cinching
Mitralign
Accucinch GDS
Millipede ring system
● Percutaneous energy-
mediated cinching
QuantumCor
ReCor
● Hybrid Mitral solutions
MiCardia
Chordal implants Transapical
● Artiﬁcial chord Neochord,
MitraFlex
Transapical-Transseptal
● Artiﬁcial chord Babic
LV LV (and MA) remodeling Mardil-BACE
Percutaneous
Valve implants Right mini-thoracotomy Endovalve-Herrmann prosth
Transapical Lutter prosthesis
Transseptal CardiaQ prosthesis
CS coronary sinus; FIM first-in-man; LV left ventricle/ventricular; MAmitral annulus; MR
NIH  National Institutes of Health.on, Massachusetts) consists of a polyurethane-silicone bolymer space-occupying buoy that is anchored at the
pex through the MV (Fig. 2) acting as a “spacer” in the
itral orifice. A transseptal approach is required to
mplant the anchor in the apex. It is undergoing phase 1
rial.
imitations. Possible limitations are thrombus formation on
he device, residual MR, or iatrogenic MS (restricted inflow
Status Major Limitations
Technologies
Randomized trial data presented Results when performed alone may not be
durable. Possibility of iatrogenic MS.
Pre-clinical development As for MitraClip
Phase 1 trial Device thrombus formation. Residual MR or
iatrogenic MS.
Animal models Scarring not precise with residual MR.
Leaﬂet/cardiac structure perforation.
FIM results. Feasibility study
ongoing.
CS at a distance from MA. Possibility of
coronary artery compression.
FIM results. Feasibility study
complete.
As above
FIM results. Feasibility study
ongoing.
As above
Animal models CS at a distance from MA. Unequal tension
on LA or MA. Device fracture or erosion, and
thrombus formation.
Animal models CS at a distance from MA. Unequal tension
on LA or MA.
FIM results Only posterior MA cinching.
FIM results As above
Pre-clinical development Feasibility and stability of ﬁxation unknown
Animal models Scarring not precise. Possible residual MR or
iatrogenic MS. Risk of cardiac structure
perforation.
Pre-clinical development As above
Pre-clinical development Not true “percutaneous” technique
Pre-clinical development As above
Pre-clinical development Residual leaﬂet prolapse or restriction with
residual MR. Thrombus formation.
Pre-clinical development As above
Temporary human implant Requires mini-thoracotomy. Long-term
effects unknown.
Technologies
Animal models Anchoring challenges. LV outﬂow
obstruction. Paravalvular leaks.
Animal models As above
Pre-clinical development As above
egurgitation; MSmitral stenosis; MVRmitral valve replacement; MVRemitral valve repair;MVRe
MVR
esis
mitral ry the “spacer”).
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4nnuloplasty—Indirect
his approach mimics surgical annuloplasty rings, which are
ommonly used for repair of both degenerative and functional
R. Because surgical annuloplasty necessitates cardiac bypass, it is
sually performed with another indication such as coronary artery
ypass graft (25). The percutaneous devices might thus offer an
lternative for those at excessive surgical-risk or who do not require
nother concomitant cardiac surgical procedure. Several percuta-
eous devices are in clinical testing, mainly for functional MR.
S Approach (CS Reshaping)
rinciple. This approach involves implantation of devices within
he CS with the aim of “pushing” the posterior annulus anteriorly,
hereby reducing the septal-lateral (anterior-posterior) dimension
f the MA. This has been demonstrated in surgical data to
mprove leaflet coaptation and decrease MR (26).
evices. The Monarc (previously Viking) system (Fig. 3) (Ed-
ards Lifesciences) consists of an outer guide catheter, a smaller
elivery catheter, and a nitinol implant. The implant has 3
ections: distal and proximal self-expanding anchors, and a spring-
Figure 1. MitraClip Device
Picture of the MitraClip device (left), the MitraClip deployed on the mitral valve le
Figure 2. Percu-Pro Device
Diagram showing transseptal implantation of the Percu-Pro (Cardiosolutions, S
face for leaﬂet coaptation (right).ike “bridge” that has shortening forces. This draws the proximal
S and distal great cardiac vein closer, indirectly displacing the
osterior annulus anteriorly. The Viking device produced an initial
avorable effect on MR, although device fracture and recurrence of
R occurred, and the feasibility study was stopped (27). The
e-engineered device (Monarc) has a reinforced bridge segment.
he phase 1 trial (Evolution) of functional MR with the Monarc
evice demonstrated implantation success in 82% (59 of 72
atients), with 13 failures (18%) due to tortuous anatomy or
nappropriate CS dimensions. Three myocardial infarctions oc-
urred due to coronary artery compression (1 received coronary
tenting, 1 treated medically, 1 fatality). Event-free survival was
1%, 72%, and 64% at 1 year and 2 and 3 years, respectively (Jan
arnek, European Society of Cardiology Congress 2010, Stock-
olm, Sweden). A larger Evolution II study is ongoing.
The Carillon Mitral Contour System (Cardiac Dimension,
nc., Kirkland, Washington) (Fig. 4) consists of self-expandable
itinol distal and proximal anchors connected by a nitinol bridge
hat are placed in the great cardiac vein and proximal CS via a
atheter-based system. Tension applied on the system results in
inching of the posterior periannular tissue and deflection of the
(middle), and the tissue bridge with a “double-oriﬁce” mitral valve (right).
ton, Massachusetts) “spacer” (left, middle), and the “spacer” providing a sur-tough
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5osterior MA anteriorly. A feasibility study showed modestly
educed septal-lateral dimension and MR when placed tempo-
arily (28). Slippage of the anchors occurred, requiring device
odification. Data from the AMADEUS trial (CARILLON
itral Annuloplasty Device European Union Study) using the
odified CARILLON XE device (Cardiac Dimension, Inc.) in
unctional MR due to dilated cardiomyopathy demonstrated
mplantation success in 62% (30 of 48 patients), with mean 1
rade reduction of MR (although it is uncertain whether this
ould be clinically meaningful). Implantation could not be
chieved in 18 patients (38%) due to access issues (CS dissection/
erforation), insufficient MR reduction, and coronary artery com-
ression. Coronary arteries were crossed frequently (36 of 43
mplant attempts), although device was recaptured in only 17%
here compromise was significant (29).
The Viacor percutaneous transvenous mitral annuloplasty de-
ice (Viacor, Inc., Wilmington, Massachusetts) (Fig. 5) uses
itinol rods of varying length and stiffness, delivered via a catheter
o the CS. This exerts outward force resulting in anterior displace-
ent of the posterior annulus. Temporary human implantation
as feasible. Subsequent permanent implantation was achieved
lthough successful only in a small proportion (9 of 27 patients)
30). Problems encountered were access issues, unsuccessful MR
eduction, unstable device, and technical delivery difficulties. Dur-
Figure 3. Monarc Device
The Monarc (Edwards Life Sciences, Irving, California) device (top) compris-
ing proximal (larger) and distal anchors and a bridge, and diagrammatical
representation after implantation in the coronary sinus.ng the study, the device remained in only 4 patients (17%) (1evice fracture, 3 underwent surgical annuloplasty, 1 died 3
onths after implant) (30).
imitations. There are major limitations to the use of CS
eshaping. The technique exploits the proximity of the CS to the
A. However, surgical anatomy suggests that the CS is located
ehind the LA wall at a significant distance from the MA (31,32).
he projection of CS annuloplasty covered just over one-half of
he total MA perimeter (32). Similarly with computed tomogra-
hy angiography, there was significant variability in the relation of
he CS to MA, and this distance was increased in severe MR with
nnular dilation (33,34). These CS devices likely shrink the MA
nly indirectly by traction on the LA wall. The annulus might in
act continue to dilate, reducing device effectiveness.
Furthermore, there is a risk that these devices might compress
coronary artery. It has been demonstrated that a diagonal or
amus branch crossed between the CS and MA in 16% of
atients, whereas it was between 64% and 80% for the left
ircumflex artery (31–34). Therefore, anatomic assessment of the
S, coronary artery, and MA relationship is mandatory before
onsidering these devices.
Other limitations include significant MA calcification, presence
f CS pacing leads, coronary venous branch point variability,
oronary venous system size constraints (risk of CS perforation),
nd structural leaflet abnormalities. This approach might theoret-
cally jeopardize future attempts at implanting cardiac resynchro-
Figure 4. Carillon XE Device
The Carillon XE (Cardiac Dimension, Inc., Kirkland, Washington) device
(top), comprising proximal (larger) and distal anchors and a bridge.
Sequence of implantation with the delivery sheath in the coronary sinus
(middle left), removal of sheath (middle right, bottom left), and only
device remaining (bottom right).
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6ization devices, although initial experience has been reassuring
35).
symmetrical Approach
rinciple. This group of devices uses the proximity of the CS to
he annulus to try to reshape the MA but in addition exert traction
orce on another portion of the LA or right atrium, resulting in
symmetrical forces. The aim is to reduce septal-lateral dimension
nd decrease MR.
evices. The percutaneous septal sinus shortening (PS3) system
Ample Medical, Foster City, California) employed a CS anchor
ositioned behind posterior leaflet, a bridge (cinching wire) con-
ecting the CS anchor to an atrial septal anchor (Amplatzer PFO
ccluder [AGA Medical, Plymouth, Minnesota]). Tension on the
ridge reduced septal-lateral dimension and reduced MR (36).
urther device development, however, has been abandoned.
Another device by St. Jude Medical (Minneapolis, Minnesota)
Fig. 6) implanted in animal models consists of 4 helical anchors,
loading spacers, a tether rope, and a locking mechanism. The
istal pair of anchors is delivered via the CS into the LV
yocardium near the posterior leaflet scallop. The proximal pair
s implanted via the right atrium into the postero-medial
rigone. The 2 pairs of anchors are connected by a cable to
ffect cinching of the postero-medial MA. Dynamic shorten-
ng can be performed manually and reversibly, and the locking
echanism is a self-retracting, nitinol structure that maintains
Figure 5. Viacor Device
The Viacor (Viacor, Inc., Wilmington, Massachusetts) PTMA rods (top left), acce
after full implantation of the rods (bottom right) in the coronary sinus.inched load (37). MThe National Institutes of Health cerclage technology directs a
uidewire via the CS into the first septal perforator of the great
ardiac vein and, under imaging, across the myocardium to
e-enter a right heart chamber. It is ensnared and exchanged for a
uture and tension-fixation device. Initial animal models have
roved promising with success in reducing MR (38).
imitations. The major drawbacks of this technology are: 1) the
S might not be in the same plane as the MA (true annuloplasty
ight not take place); and 2) unequal tension exerted on the CS
r LA, with unknown long-term consequences. There is a
heoretical risk of device erosion or fracture and possible thrombus
ormation on the connecting cable.
nnuloplasty—Direct:
ercutaneous Mechanical
inching Approach
rinciple. This technology reshapes the MA directly without
sing the CS, approaching the MA from the LV or the LA side.
utures or some other device are implanted onto the MA itself
nd used to directly “cinch” the MA. These technologies might be
ble to address the potential limitations of the indirect annulo-
lasty method and would be most useful for functional MR
although it could be employed in degenerative MR).
evices. The Mitralign device (Mitralign, Tewksbury, Massa-
husetts) (Fig. 7) gains access to the annulus from the transven-
ricular approach. Anchors are placed directly on the posterior
the coronary sinus (bottom left), introduction of the rods (top right), andss toA and connected with a suture, creating a “purse-string” to
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7inch the MA. Retrograde LV access to the periannular space has
een achieved reliably with successful first-in-man (FIM) results
unpublished data).
The Accucinch Annuloplasty System (Guided Delivery Sys-
ems, Santa Clara, California) uses a transventricular approach and
as FIM results (unpublished data). The posterior annulus is
inched circumferentially from trigone to trigone (Fig. 8), with
mprovement in MR.
The Millipede system (Millipede, LLC, Ann Arbor, Michi-
an) involves placement of a novel repositionable and retrievable
nnular ring with a unique attachment system via percutaneous
transseptal) or minimally invasive methods.
nnuloplasty—Direct:
ercutaneous Energy-Mediated
inching Approach
rinciple. Heat energy is applied to the MA, causing
carring and shrinkage of the MA.
evices. By the transatrial (transseptal) route, the Quan-
umCor (QuantumCor, Lake Forest, California) device
Fig. 9) effects direct annuloplasty by use of radiofrequency
nergy to cause scarring and constriction of the MA. It has
loop tip that contains electrodes and thermocouples to
egulate the amount of energy delivered. This device has
een tested in animal models with reduction of MA
Figure 6. St. Jude Device
The St. Jude Medical device (St. Jude Medical, Minneapolis, Minnesota)
(bottom left arrow denotes distal anchors near P2, bottom right arrow
denotes proximal anchors near the postero-medial trigone).istances and nonischemic MR (39). cThe ReCor (ReCor, Paris, France) device delivers high-
ntensity focused ultrasound circumferentially and perpen-
icularly to the catheter shaft to induce tissue heating and
ollagen (and thus MA) shrinkage.
imitations. The limitation of the Mitralign and Accucinch
evices is that only the posterior MA is cinched. Optimal
urgical correction is currently thought to be obtained by
erforming an annuloplasty with a complete rather than a
artial ring (32), because the intertrigonal distance is not fixed
s previously believed (7). The Millipede system overcomes
his issue, but feasibility and stability of annular fixation is
nknown. Scarring induced by the QuantumCor and Recor
evices might not be precisely controlled, and over-constriction
ith resultant MS or under-correction with residual MR could
onceivably occur. Damage or perforation of neighboring
ardiac structures including the CS is possible, although this
as not observed in animal models (39).
nnuloplasty—Direct:
ybrid Approach
rinciple. An annuloplasty ring is implanted surgically and
an be subsequently adjusted via transseptal access if MR
ecurs or worsens.
evices. The Adjustable Annuloplasty Ring (MitralSolu-
ions, Fort Lauderdale, Florida) (Fig. 10) is implanted
urgically and can be adjusted with a mechanical rotating
able, whereas the Dynamic annuloplasty Ring System
MiCardia, Inc., Irving, California), which recently had
IM results, is adjusted with radiofrequency energy.
imitations. Although this approach seems an effective way of
ustomizing device size-shape to each patient under real-life
oading conditions, initial surgical implantation is required.
herefore, these technologies are more of a hybrid technique.
t is conceivable that they might evolve into true percutaneous
echnologies. Both are in pre-clinical development.
hordal Implantation
rinciple. Synthetic chords or sutures are implanted either
rom a transapical or transseptal approach and anchored
nto the LV myocardium at one end, with the leaflet at the
ther. The length of the chord is then adjusted to achieve
ptimal leaflet coaptation and reduce MR. This approach
ould be mainly for degenerative MR.
evices. There are 3 devices currently in development: the
ransapically delivered MitraFlex (TransCardiac Therapeu-
ics) and NeoChord (Neochord, Inc., Minnetonka, Minne-
ota) devices, and the transapical-transseptal route of the
abic device (Fig. 11). The MitraFlex and Neochord
evices place an anchor in the inner LV myocardium and
nother on the leaflet via a transapical approach and connect
he 2 with a synthetic “chord.” In the Babic device, 2
ontinuous suture tracks are created from the LV puncture
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8Figure 7. Mitralign Device
Figures showing the Mitralign device (Mitralign, Tewksbury, Massachusetts) gaining access via the left ventricle (top left), placement of anchors on the posterior
mitral annulus (top right, bottom left), and after cinching (bottom right).Figure 8. Accucinch Annuloplasty System
Figure (left) showing action of the Accucinch device (Guided Delivery Systems, Santa Clara, California) and animal model (right) of the deployed Accucinch sys-
tem (arrows denote suture along the posterior annulus).
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9ite through the puncture of the target leaflet and are
xteriorized via the transseptal route. A pledget is apposed
nto the exteriorized venous sutures and anchored onto the
trial side of the leaflet by retracting the guiding sutures
rom the epicardial end. A polymer tube is then interposed
etween the leaflet and free myocardial wall and secured at
he epicardial surface by an adjustable knob.
imitations. Possible problems that might be encoun-
ered with this technology are residual leaflet prolapse
Figure 9. QuantumCor Device
The QuantumCor device (QuantumCor, Lake Forest, California) (left) and devic
Figure 10. Adjustable Annuloplasty Ring SystemThe Adjustable Annuloplasty Ring (MitralSolutions, Fort Lauderdale, Florida) (top left); thartificial chords too long) or leaflet restriction (chords
oo short) and residual MR (7) and device thrombus
ormation.
V Remodeling
rinciple. A device is used to reduce the anterior–posterior
imension of the LV. This indirectly decreases the septal-
ateral annular distance and also brings the LV papillary
lied to the mitral annulus via the transseptal approach (right).e connecting cable (top right). The cable connected to the ring (bottom).
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10uscles closer to the leaflets. This approach seems suitable
ainly for functional MR due to ischemic or cardiomyopathic
tiologies.
The percutaneous iCoapsys technology was based on the
oapsys surgical system (Myocor, Maple Grove, Minnesota),
hich places pads on either side of the LV with a cord passing
hrough the LV cavity to apply tension to the MA and basal
V wall, moving the posterior leaflet to better coapt with the
nterior leaflet. Surgical data demonstrated implantation
afety, reduction in MR, and positive LV remodeling (40).
Figure 11. Transcatheter Chordal Implants
The MitraFlex device sheath (TransCardiac Therapeutics, Atlanta, Georgia) (top
(top right); the NeoChord device (Neochord, Inc., Minnetonka, Minnesota) implthough transpericardial percutaneous device implantation nia a sub-xiphoid approach was feasible in animal models (41),
evice development has been discontinued.
The Mardil-BACE (Mardil, Inc., Morrisville, North Caro-
ina) (Fig. 12) device requires a mini-thoracotomy but is
mplanted on a beating heart. A silicone band is placed around
he atrioventricular groove with built-in inflatable chambers
laced on the MA. This reshapes the MA for better leaflet
oaptation and can be remotely adjusted after implantation. No
oronary artery compromise was shown in animal models, and
roof-of-concept was demonstrated in 15 patients, although
clip for leaﬂet plication (top middle), and artiﬁcial chord implantation
from a transapical approach (middle); the Babic device (bottom).left),o further details were made available (unpublished data).
L
o
T
D
i
f
t
i
r
e
a
a
(
u
o
U
o
b
(
o
t
n
f
a
P
A
b
D
i
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 1 , 2 0 1 1 Chiam and Ruiz
J A N U A R Y 2 0 1 1 : 1 – 1 3 Percutaneous Mitral Valve Repair
11imitations. There are sparse clinical data, and longer-term
utcomes and adverse events are unknown.
arget Patient Populations
espite the enthusiasm generated by these emerging devices, it
s important to consider what patient populations are suitable
Figure 12. Mardil-BACE Device
The Mardil-BACE device (Mardil, Inc., Morrisville, North Carolina) consists of
a silicone band with inﬂatable chambers implanted around the atrioventric-
ular groove.
Figure 13. Endovalve-Herrmann ProsthesisThe Endovalve-Herrmann prosthesis (top right), loaded in the delivery sheath (top lor these technologies. The 2 etiologies of MR most amenable
o surgical repair are degenerative and functional. Annuloplasty
s the main technique used in functional MR, whereas leaflet
epair is also usually performed in degenerative MR.
In the EuroHeart survey, degenerative and functional
tiologies accounted for 61% and 7%, respectively (2). From
global perspective, however, rheumatic disease (which has
low probability of repair) will take on greater prominence
up to 50%) (42).
Despite numerous surgical techniques and performance
nder direct vision, repair was performed in just under
ne-half of patients with MR who required surgery in the
.S. and Europe (2,43), with unfavorable anatomy, absence
f surgical expertise, and failure of conservative surgery
eing the major reasons (2). In addition, certain pathologies
rheumatic, endocarditic, inflammatory, and so forth) are
ften not repairable. Therefore, current percutaneous op-
ions might be useful only in a selected patient pool. The
eed for a cautious approach to percutaneous MVRe is
urther emphasized by the excellent results of surgical repair
nd the low perioperative mortality (44).
ercutaneous MVR
combination of percutaneous techniques will most likely
e needed if results comparable to surgery are expected.
espite the armamentarium available to surgeons and the
ncreasing preference for repair, in a significant proportioneft), and sequence of implantation (bottom left and right).
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12f patients, surgical MVRe is not possible or fails, and MVR
s required (45).
In the future, the novel technology of percutaneous MVR
ight become a possible alternative in a selected group of
atients with a low probability of successful repair. However,
he challenges are formidable. The MA has an asymmetrical
addle shape, and different anchoring designs might be re-
uired for different MR etiologies. Left ventricular outflow
bstruction might occur due to retained native valve tissue.
aravalvular leaks might also pose a problem.
There are 3 devices in development. The Endovalve-
errmann prosthesis (Endovalve Inc., Princeton, New
ersey) (Fig. 13) is implanted from the LA side via a right
ini-thoracotomy on a beating heart. The device is a
oldable nitinol structure that attaches to the native valve
ith specially designed grippers, is fully valve sparing,
nd repositionable before release. Animal models have
een successful, and a true percutaneous version is
lanned. The Lutter prosthesis, a nitinol stent-valve, has
een implanted transapically in porcine models (46). The
ardiAQ (CardiAQ Valve Technologies, Inc., Winches-
er, Massachusetts) prosthesis (Fig. 14) is in pre-clinical
evelopment and is delivered transseptally. Given the
omplexities involved with this approach, further im-
rovements to these technologies will be required before
linical testing.
onclusions
he field of percutaneous transcatheter MVRe is evolving
xponentially. These emerging technologies can be classified
y their site of action and device mechanism. The proposed
lassification is based on therapies aimed at the leaflets
leaflet plication, leaflet coaptation, leaflet ablation), annu-
oplasty (indirect: CS approach or asymmetrical approach;
Figure 14. CardiAQ Prosthesis
The CardiAQ (CardiAQ Valve Technologies, Inc., Winchester, Massachusetts) pro
(middle) and superior (right) surfaces of the mitral annulus.nd direct: true percutaneous or hybrid), percutaneoushords, and LV remodeling. Percutaneous edge-to-edge
eaflet repair has been shown to be noninferior to surgery in
randomized trial. Several other technologies—including
arious direct and indirect annuloplasty and LV remodeling
evices—have achieved first-in-man results or are in pre-
linical testing. Most likely a combination of these technol-
gies will be required for satisfactory MVRe. However, for
any patients repair will not be possible, and MVR will be
equired. Although there are significant challenges, several
ercutaneous MVR prototypes are already in development.
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